These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 24522994)

  • 1. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy.
    Lee H; Ahn YC; Pyo H; Kim B; Oh D; Nam H; Lee E; Sun JM; Ahn JS; Ahn MJ; Park K; Choi YS; Kim J; Zo JI; Shim YM
    Ann Surg Oncol; 2014 Jun; 21(6):2083-90. PubMed ID: 24522994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.
    Suntharalingam M; Paulus R; Edelman MJ; Krasna M; Burrows W; Gore E; Wilson LD; Choy H
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):456-63. PubMed ID: 22543206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
    Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
    Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
    Sher DJ; Fidler MJ; Seder CW; Liptay MJ; Koshy M
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):307-16. PubMed ID: 25838187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Number of mediastinal lymph nodes in non-small cell lung cancer: a Gaussian curve, not a prognostic factor.
    Riquet M; Legras A; Mordant P; Rivera C; Arame A; Gibault L; Foucault C; Dujon A; Le Pimpec Barthes F
    Ann Thorac Surg; 2014 Jul; 98(1):224-31. PubMed ID: 24820386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent of removal for mediastinal nodal stations for patients with clinical stage I non-small cell lung cancer: effect on outcome.
    Jeon HW; Moon MH; Kim KS; Kim YD; Wang YP; Park HJ; Park JK
    Thorac Cardiovasc Surg; 2014 Oct; 62(7):599-604. PubMed ID: 24420680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved.
    Matsunaga T; Suzuki K; Takamochi K; Oh S
    Eur J Cardiothorac Surg; 2014 Jul; 46(1):86-91. PubMed ID: 24321998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer.
    Sakao Y; Miyamoto H; Yamazaki A; Oh T; Fukai R; Shiomi K; Saito Y
    Ann Thorac Surg; 2006 Jan; 81(1):292-7. PubMed ID: 16368383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of radiotherapy between postoperative mediastinal lymph node recurrence and stage III disease in non-small cell lung cancer patients.
    Imai H; Murakami H; Yoshino R; Mori K; Sumita K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Harada H; Naito T; Kaira K; Tomizawa Y; Ohde Y; Matsuura M; Endo M; Saito R; Nakajima T; Takahashi T
    J BUON; 2016; 21(2):333-40. PubMed ID: 27273942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.
    Mamon HJ; Yeap BY; Jänne PA; Reblando J; Shrager S; Jaklitsch MT; Mentzer S; Lukanich JM; Sugarbaker DJ; Baldini EH; Berman S; Skarin A; Bueno R
    J Clin Oncol; 2005 Mar; 23(7):1530-7. PubMed ID: 15735128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
    Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer.
    Kang CH; Ra YJ; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Oct; 86(4):1092-7. PubMed ID: 18805138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of predictive factors for postoperative survival for non small cell lung carcinoma patients with unexpected mediastinal lymph nodes metastasis.
    Wang S; Zhou W; Zhang H; Zhao M; Chen X
    Thorac Cardiovasc Surg; 2014 Mar; 62(2):126-32. PubMed ID: 23585223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.
    Yoo C; Yoon S; Lee DH; Park SI; Kim DK; Kim YH; Kim HR; Choi SH; Kim WS; Choi CM; Jang SJ; Song SY; Kim SS; Choi EK; Lee JC; Suh C; Lee JS; Kim SW
    Clin Lung Cancer; 2015 Nov; 16(6):e203-12. PubMed ID: 25997733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.
    Okada M; Sakamoto T; Yuki T; Mimura T; Nitanda H; Miyoshi K; Tsubota N
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):825-30. PubMed ID: 15821650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.